<p>Clinicopathologic Characteristics of <i>ROS1</i> and <i>ALK</i>-rearranged adenocarcinomas</p
†<p>CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.</...
AbstractChromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described i...
<p><i>Abbreviations:</i> NSCLC, non-small-cell lung cancer; Ad, adenocarcinoma; SCC, squamous cell c...
BACKGROUND: ROS1 rearrangement accounts for 1%-2% of non-small cell lung cancer (NSCLC) with a remar...
IntroductionWe sought to evaluate the clinical and pathological characteristics of patients with non...
Introduction: We sought to evaluate the clinical and pathological characteristics of patients with n...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
Background: ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases ...
<p>(A-D) It shows the light micrograph, revealing adenocarcinoma (HE 200 ×). (E-H) Red probes are hy...
AIMS:To identify the clinical and histological characteristics of ROS1-rearranged non-small-cell lun...
<p>One area of a <i>ROS1</i>-rearranged tumor shows a solid area with intense immunostaining for ROS...
<div><p>To evaluate the frequency and clinicopathological features of <i>ROS1</i> and <i>RET</i> rea...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
†<p>CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.</...
AbstractChromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described i...
<p><i>Abbreviations:</i> NSCLC, non-small-cell lung cancer; Ad, adenocarcinoma; SCC, squamous cell c...
BACKGROUND: ROS1 rearrangement accounts for 1%-2% of non-small cell lung cancer (NSCLC) with a remar...
IntroductionWe sought to evaluate the clinical and pathological characteristics of patients with non...
Introduction: We sought to evaluate the clinical and pathological characteristics of patients with n...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
Background: ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases ...
<p>(A-D) It shows the light micrograph, revealing adenocarcinoma (HE 200 ×). (E-H) Red probes are hy...
AIMS:To identify the clinical and histological characteristics of ROS1-rearranged non-small-cell lun...
<p>One area of a <i>ROS1</i>-rearranged tumor shows a solid area with intense immunostaining for ROS...
<div><p>To evaluate the frequency and clinicopathological features of <i>ROS1</i> and <i>RET</i> rea...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
†<p>CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.</...
AbstractChromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described i...
<p><i>Abbreviations:</i> NSCLC, non-small-cell lung cancer; Ad, adenocarcinoma; SCC, squamous cell c...
DOI
Add to ORKG